factory supply 99% Tenofovir Alafenamide Fumarate / TAF powder

factory supply 99% Tenofovir Alafenamide Fumarate / TAF powder

Min.Order / FOB Price:Get Latest Price

1 Kilogram	FOB Price:USD 1.0000 -999.0000

1 Kilogram

FOB Price:USD 1.0000 -999.0000

Min.Order :1 Kilogram
Purity: 99% up
Payment Terms : L/C,D/A,D/P,T/T,Other

Keywords

Tenofovir Alafenamide Fumarate / TAF factory supply 99%

Quick Details

Appearance:White powder
Application:Medicine Grade
PackAge:1kg/bag ;5kg/drum:25KG/drum
ProductionCapacity:20|Metric Ton|Month
Storage:The product may be stored for 12 months from the date of manufacture in the unopened original container and at room temperature.
Transportation:in low tempreture

Superiority:

Why is SINOWAY:

1) Specialized in pharmaceutical and healthcare industrial for 34 years.

2) ISO 9001:2015 & SGS audited supplier .

3) Accept various payment terms : T.T 30-60 days.

4) We have warehouse in USA with quickly shipment .

5) We can do different terms of FOB ,CIF/CIP ,DDP ...

Why choose us

1. best quality in your requirement
2. competitive price in china market
3. mature technical support
4. professional logistic support
5. full experience of large numbers containers loading in chinese sea port
6. fast shipment by reputed shipping line
7. packing with pallet as buyer's special request
8. best service after shipment with email !
9. cargoes together with container after-sales service available
10. full experience in export
11. raw materials from chinese origin

Details:

Product Information

Product name	Tenofovir Alafenamide Fumarate / TAF
CAS No.	1392275-56-7
Molecular Formula	2(C21H29N6O5P).C4H4O4
Molecular Weight	1069.00
Quality Standard	98% up, Medicine Grade
Appearance	White powder

COA of Tenofovir Alafenamide Fumarate / TAF

Usage

Function of Tenofovir Alafenamide Fumarate / TAF

Tenofovir Alafenamide Fumarate / TAF is a novel nucleotide reverse transcriptase inhibitor for the treatment of chronic hepatitis B virus infection and compensatory liver disease.

Tenofovir alafluamine fumarate is an oral prodrug of tenofovir (TFV), a modified version of the commercially available drug tenofovir disoproxil fumarate (TDF). Compared with TDF, TAF has a smaller clinical dose and is easier to enter the cell. The virus acts more strongly and the adverse reactions are reduced.

API TAF was approved by the COS on November 10, 2016 for the treatment of adult patients with chronic hepatitis B infection. PMDA was approved on December 19, 2016 and approved by EMA in 2017.1.9, becoming the first hepatitis B drug approved for listing in Europe in the past 10 years. Approved for the treatment of HIV infection, all three drugs are based on tenofovir alafenamide fumarate.